Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Hormones – e.g. – prolactin – thymosin – growth factors – etc.
Reexamination Certificate
2005-02-28
2008-10-21
Landsman, Robert (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Hormones, e.g., prolactin, thymosin, growth factors, etc.
C530S300000, C530S350000
Reexamination Certificate
active
07439333
ABSTRACT:
Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA (RNA) encoding such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.
REFERENCES:
patent: 5073492 (1991-12-01), Chen et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5234908 (1993-08-01), Szabo et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5283354 (1994-02-01), Lemischka
patent: 5326695 (1994-07-01), Andersson et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5633147 (1997-05-01), Meissner et al.
patent: 5652225 (1997-07-01), Isner
patent: 5661133 (1997-08-01), Leiden et al.
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5792453 (1998-08-01), Hammond et al.
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 5861301 (1999-01-01), Terman et al.
patent: 5932540 (1999-08-01), Hu et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 6040157 (2000-03-01), Hu et al.
patent: 6121246 (2000-09-01), Isner
patent: 6130071 (2000-10-01), Alitalo et al.
patent: 6221839 (2001-04-01), Alitalo et al.
patent: 6245530 (2001-06-01), Alitalo et al.
patent: 6361946 (2002-03-01), Alitalo et al.
patent: 6403088 (2002-06-01), Alitalo et al.
patent: 6451764 (2002-09-01), Lee et al.
patent: 6608182 (2003-08-01), Rosen et al.
patent: 6645933 (2003-11-01), Alitalo et al.
patent: 6734285 (2004-05-01), Hu et al.
patent: 7109308 (2006-09-01), Rosen et al.
patent: 7115392 (2006-10-01), Rosen et al.
patent: 7153827 (2006-12-01), Hu et al.
patent: 7153942 (2006-12-01), Hu et al.
patent: 7186688 (2007-03-01), Hu et al.
patent: 7208582 (2007-04-01), Rosen et al.
patent: 7223724 (2007-05-01), Alderson et al.
patent: 7227005 (2007-06-01), Hu et al.
patent: 7273751 (2007-09-01), Coleman
patent: 2003/0215921 (2003-11-01), Coleman
patent: 2004/0214286 (2004-10-01), Hu et al.
patent: 2005/0059117 (2005-03-01), Rosen et al.
patent: 2005/0181979 (2005-08-01), Alderson et al.
patent: 2005/0192429 (2005-09-01), Rosen et al.
patent: 2005/0232921 (2005-10-01), Rosen et al.
patent: 2005/0287143 (2005-12-01), Rosen et al.
patent: 2006/0014252 (2006-01-01), Lyman
patent: 2006/0025331 (2006-02-01), Hu et al.
patent: 2006/0057117 (2006-03-01), Coleman
patent: 710696 (1999-09-01), None
patent: 0 186 084 (1986-07-01), None
patent: 0 399 816 (1990-11-01), None
patent: 0 476983 (1992-03-01), None
patent: 0 506477 (1992-09-01), None
patent: 64-38100 (1989-02-01), None
patent: 2-117698 (1990-05-01), None
patent: WO-91/02058 (1991-02-01), None
patent: WO-92/14748 (1992-09-01), None
patent: WO 94/11506 (1994-05-01), None
patent: WO-95/19985 (1995-07-01), None
patent: WO-95/24414 (1995-09-01), None
patent: WO-95/24473 (1995-12-01), None
patent: WO-96/05856 (1996-02-01), None
patent: WO-96/39515 (1996-12-01), None
patent: WO-97/00271 (1997-01-01), None
patent: WO-97/05250 (1997-02-01), None
patent: WO-97/08320 (1997-03-01), None
patent: WO-97/09427 (1997-03-01), None
patent: WO-97/17442 (1997-05-01), None
patent: WO-97/19694 (1997-06-01), None
patent: WO-98/06844 (1998-02-01), None
patent: WO-98/07832 (1998-02-01), None
patent: WO-98/24811 (1998-06-01), None
patent: WO-98/33917 (1998-06-01), None
patent: WO-98/39035 (1998-09-01), None
patent: WO-98/49300 (1998-11-01), None
patent: WO-98/55619 (1998-12-01), None
patent: WO-98/56936 (1998-12-01), None
patent: WO-99/02545 (1999-01-01), None
patent: WO-99/08522 (1999-02-01), None
patent: WO-99/20749 (1999-04-01), None
patent: WO-99/21590 (1999-05-01), None
patent: WO-99/46364 (1999-09-01), None
patent: WO 00/45835 (2000-08-01), None
patent: WO-00/73430 (2000-12-01), None
patent: WO-00/75163 (2000-12-01), None
patent: WO-01/57226 (2001-08-01), None
patent: WO-01/58956 (2001-08-01), None
patent: WO 02/11769 (2002-02-01), None
patent: WO 02/083704 (2002-10-01), None
patent: WO 02/083849 (2002-10-01), None
patent: WO 02/083850 (2002-10-01), None
patent: WO 03/097660 (2003-11-01), None
patent: 9-403464 (1996-01-01), None
Joukov, V et al. The EMBO J. 15(7):1751, 1996.
U.S. Appl. No. 09/257,272, inventors Hu et al., filed Feb. 25, 1999 (Not Published).
U.S. Appl. No. 09/499,468, inventors Alderson et al., filed Feb. 7, 2000 (Not Published).
U.S. Appl. No. 11/730,696, inventors Rosen et al., filed Apr. 3, 2007 (Not Published).
Anderson, W.F., “Human gene therapy,”Nature 392:25-30, Macmillan Magazines Ltd. (Apr. 1998).
Borg, J.-P., et al., “Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase,”Oncogene 10:973-984, Stockton Press (Mar. 1995).
Capogrossi, M.C., “Gene Therapy of Coronary Artery Disease,” Project No. Z01 AG00811-01, Abstract (Jan. 1994).
Capogrossi, M.C., “Gene Therapy of Coronary Artery Disease,” Project No. Z01 AG00811-02, Abstract (Jan. 1995).
Choi, I.H., et al., “Angiogenesis and Mineralization During Distraction Osteogenesis,”J. Korean Med. Sci. 17:435-447, The Korean Academy of Medical Sciences (Aug. 2002).
Declaration of Dr. Kari Alitalo, In re of: U.S. Appl. No. 08/585,895, Alitalo et al., filed Jan. 12, 1996, submitted Nov. 26, 1997.
Dias, S., et al., “Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy,”Blood 99:2179-2184, The American Society of Hematology (Mar. 2002).
English language abstract of JP 64-38100 A, cited as document FP2 on Form PTO/SB/08A, Derwent Accession No. 1989-088700/198912.
English language abstract of JP 2-117698 A, cited as document FP3 on Form PTO/SB/08A, Derwent Accession No. 1990-181364/199024.
Danis, R.P., et al., “Anti-angiogenic therapy of proliferative diabetic retinopathy,”Exp. Opin. Pharma. 2:395-407, Ashley Publications Ltd. (Mar. 2001).
Enholm, B., et al., “Vascular Endothelial Growth Factor-C: A Growth Factor for Lymphatic and Blood Vascular Endothelial Cells,”Trends Cardiovasc. Med. 8:292-297, Elsevier Science Inc. (Oct. 1998).
Fan, T.-P.D., et al., “Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy,”Trends Pharmaco. Sci. 16:57-66, Elsevier Science Ltd. (Feb. 1995).
Ferrara, N., “Vascular Endothelial Growth Factor and the Regulation of Angiogenesis,”Recent Prog. Hormone Res. 55:15-36, The Endocrine Society (Mar. 2000).
Halin, C. and Neri, D., “Antibody-Based Targeting of Angiogenesis,”Crit. Rev. Ther. Drug Carrier Syst. 18:299-339, Begell House, Inc. (Aug. 2001).
Isner, J.M., et al., “Arterial Gene Therapy for Therapeutic Angiogenesis in Patients With Peripheral Artery Disease,”Circulation 91:2687-2692, American Heart Association, Inc. (Jun. 1995).
Isner, J.M. and Feldman, L.J., “Gene therapy for arterial disease,”Lancet 344:1653-1654, The Lancet Ltd. (Dec. 1994).
Isner, J.M., et al., “Physiologic Assessment of Angiogenesis by Arterial Gene Therapy with Vascular Endothelial Growth Factor,”J. Cell. Biochem.(Suppl. 21A):378, Abstract C6-215, Wiley-Liss (Mar.-Apr. 1995).
Isner, J.M., “Therapeutic Angiogenesis in Vascular Medicine,” Project No. R01 HL53354-01, Abstract (Mar. 1995).
Kubo, H., et al., “Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea,”Proc. Natl. Acad. Sci. 99:8868-8873, The National Academy of Sciences (Jun. 2002).
Kuzuya, M. and Kinsella, J.L., “Induction of Endothelial Cell Differentiation in Vitro by Fibroblast-Derived Soluble F
Cao Liang
Hu Jing-Shan
Rosen Craig A.
Human Genome Sciences Inc.
Landsman Robert
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Vascular endothelial growth factor 2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vascular endothelial growth factor 2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vascular endothelial growth factor 2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4006383